文献速递甲状腺与颈部外科围术期管理与 ERAS

全甲状腺切除术中近红外自体荧光甲状旁腺识别成本效果分析

Cost-effectiveness of Near-infrared Autofluorescence (NIRAF) in Total Thyroidectomy.
PubMed 文献 · Ann Surg · 2026-09-11

本研究从第三方支付方视角,用决策树模型评估全甲状腺切除术中近红外自体荧光(NIRAF)辅助识别甲状旁腺相对肉眼识别的成本效果,时间跨度1年。基础分析中NIRAF组1年预期成本566.99美元、肉眼组122.51美元,NIRAF组QALY更高(0.994对0.989),ICER为每增加1个QALY支付85,042美元,低于10万美元/ QALY的支付意愿阈值。敏感性分析显示只要NIRAF价格低于578.00美元即维持成本效果。

要点

  • NIRAF组1年成本566.99美元高于肉眼组122.51美元,但QALY略高(0.994对0.989)。
  • ICER为85,042美元/QALY,低于10万美元/QALY支付意愿阈值。
  • NIRAF价格低于578.00美元时敏感性分析仍支持其成本效果。

核心结论

  • 在全甲状腺切除术中,NIRAF相对肉眼识别甲状旁腺在10万美元/QALY支付意愿阈值下具有成本效果,但结果对价格和支付方阈值高度敏感。

研究设计与样本

  • 成本效果分析,采用决策树模型,从第三方支付方视角参数化建模,时间跨度1年,以ICER为效果指标、支付意愿阈值为10万美元/QALY。

主要发现

  • 基础分析中肉眼组1年预期成本为122.51美元,低于NIRAF组的566.99美元。
  • NIRAF组QALY为0.994,高于肉眼组的0.989。
  • NIRAF的ICER为每增加1个QALY支付85,042美元,低于假设的支付意愿阈值。
  • 敏感性分析提示只要NIRAF价格低于578.00美元,其仍具成本效果。

关键数值与推荐

  • 支付意愿阈值:每增加1个QALY支付100,000美元。
  • 基础分析1年预期成本:肉眼组122.51美元,NIRAF组566.99美元。
  • QALY:NIRAF组0.994,肉眼组0.989。
  • ICER:85,042美元/QALY。
  • 敏感性分析价格界值:578.00美元。

临床怎么用

  • 可将NIRAF作为全甲状腺切除术中辅助识别甲状旁腺、降低低钙血症相关负担的候选技术,但决策需结合本地NIRAF采购价格与支付方阈值。

局限性

  • 成本效果结论对NIRAF价格、支付方支付意愿阈值以及暂时性或永久性低钙血症的真实发生率高度敏感。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Hypocalcemia is a common complication following total thyroidectomy. Near-infrared autofluorescence (NIRAF) is a newer technology that aids in intraoperative identification of parathyroid glands. In this study, we aim to estimate the cost-effectiveness of NIRAF relative to naked-eye visualization of parathyroid glands during total thyroidectomy from a third-party payor perspective. STUDY DESIGN: Cost-effectiveness analysis. SETTING: Decision analysis. METHODS: A decision tree was used to model costs, quality-adjusted life years (QALY), and cost-effectiveness of NIRAF. The model was parameterized using the best available literature on the probability of hypocalcemia, likelihood of hospitalization, cost of treatment for hypocalcemia, and utilities for transient and permanent hypocalcemia. Expected costs and utility were estimated over a 1-year time horizon, and cost-effectiveness was measured using the incremental cost-effectiveness ratio (ICER) with a willingness-to-pay threshold of $100,000 per additional QALY gained. RESULTS: In the base case, the expected 1-year cost for naked-eye thyroidectomy was $122.51, which was lower than that of NIRAF ($566.99). NIRAF yielded more QALYs (0.994 vs. 0.989). The ICER for NIRAF was $85,042 per QALY gained, which is below the assumed willingness-to-pay threshold. Sensitivity analyses suggested that NIRAF remained cost-effective, as long as the price remained below $578.00. CONCLUSIONS: Cost-effectiveness of NIRAF is highly sensitive to the price and a payor's willingness-to-pay threshold as well as the true rate of transient or permanent hypocalcemia. To our knowledge, this is the first cost-effectiveness analysis of NIRAF during total thyroidectomy in the United States.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Kulkarni P, Hollenbeak CS, Goldenberg D, et al. Cost-effectiveness of Near-infrared Autofluorescence (NIRAF) in Total Thyroidectomy. Ann Surg. 2026. PMID: 42723122. doi:10.1097/SLA.0000000000007220

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。